Investor RelationsIR News
-
Allocation of Stock-Based Compensation Stock OptionsPDF
（194KB）PDF
（194KB） -
Long-Term Vision for 2030 and Medium-Term Business PlanPDF
（194KB）PDF
（194KB）
-
Financial Summary for the Fiscal Year Ended March 31, 2021PDF
（194KB）PDF
（194KB）
-
FY2020 Financial ResultsPDF
（194KB）PDF
（194KB）
-
Sawai Group Holdings Announces Forecast of Business Results and Dividends for Fiscal 2021PDF
（194KB）PDF
（194KB）
-
Sawai Group Holdings Announces Posting of Impairment Loss and Revision of Forecast at Sawai PharmaceuticalPDF
（194KB）PDF
（194KB）
-
Notice of Company Split (Simplified Absorption-type Company Split)PDF
（194KB）PDF
（194KB）
-
Notice of Management Structure upon Transition into a Holding Company StructurePDF
（194KB）PDF
（194KB）
-
Notice of Cancellation of Treasury Shares and Treasury Stock Acquisition RightsPDF
（194KB）PDF
（194KB）
-
Sawai Receives Approvals for Eight Generic Drugs with 20 StrengthsPDF
（194KB）PDF
（194KB）
-
FY2020 Financial Results for the 3rd QuarterPDF
（194KB）PDF
（194KB）
-
Summary of Financial Results for the 3rd Quarter of FY 2020PDF
（194KB）PDF
（194KB）
-
Sawai and Neurolief enter into Exclusive Development and Marketing Agreement for RelivionPDF
（194KB）PDF
（194KB）